Description
Eszopiclone (Eszopiclone) 3 mg
Eszopiclone is a prescription sedative-hypnotic medicine used for the treatment of insomnia in adults. The verified product form here is a 3 mg oral tablet. Official prescribing information describes eszopiclone as a medicine that can decrease sleep latency and improve sleep maintenance in controlled studies.
Active Ingredient and Medicine Class
The active ingredient is eszopiclone. It belongs to the nonbenzodiazepine hypnotic group, often described as a “Z-drug.” It is a cyclopyrrolone derivative related to zopiclone, but it is not a benzodiazepine.
Established Medical Uses
Eszopiclone is established for the treatment of insomnia. Prescribing information indicates that it helps with both falling asleep and staying asleep. The evidence base supporting approval includes controlled outpatient and sleep-laboratory studies in adults, with efficacy assessments extending up to several months in some trials.
Its use is not established for children, and the available official information is focused on adult insomnia.
How It Works
The exact hypnotic mechanism is not fully known. Current prescribing information states that eszopiclone is believed to act through interaction with GABA-receptor complexes near or allosterically coupled to benzodiazepine receptor binding sites. In practical terms, this means it enhances central nervous system inhibitory signaling in a way that promotes sleep. Although it acts at a similar receptor system to benzodiazepines, its chemical structure is different.
Important Safety Information
Eszopiclone carries important safety warnings. It is contraindicated in people who have had complex sleep behaviors after taking the medicine, and in people with known hypersensitivity to eszopiclone. Complex sleep behaviors may include sleep-walking, sleep-driving, or other activities while not fully awake, and serious injury has been reported.
The medicine can cause next-day impairment, especially at higher strengths. This includes reduced alertness, slower reaction time, and impaired driving ability the next morning. The risk is greater when eszopiclone is combined with alcohol or other central nervous system depressants, including benzodiazepines, opioids, and some antidepressants.
Clinically significant interactions are also noted with medicines that affect metabolism. Potent CYP3A4 inhibitors can increase exposure to eszopiclone, while rifampin can reduce its effect. Prescribing information also advises caution in patients with severe hepatic impairment and in people with compromised respiratory function.
Eszopiclone is a controlled substance because of the potential for abuse and dependence. Risk is higher in people with a history of substance misuse or psychiatric illness.
Possible Side Effects
Common adverse effects reported in prescribing information include unpleasant taste, headache, somnolence, dizziness, dry mouth, and nausea-like or upper respiratory symptoms. Some people may also experience anxiety, rash, or hallucinations.
More serious reactions can include complex sleep behaviors, excessive sedation, memory problems, abnormal thinking or behavior, allergic reactions such as angioedema, and signs of misuse or dependence. Because eszopiclone can impair alertness, caution is warranted with activities requiring full mental sharpness.
Scientific Evidence
Peer-reviewed clinical reviews and meta-analyses support eszopiclone’s short- to medium-term efficacy for insomnia, with improvements in sleep onset and sleep maintenance compared with placebo. Published evidence also suggests benefits in subjective sleep measures and wake after sleep onset across several study durations. These findings support the established role of eszopiclone as a hypnotic option, while also reinforcing the need to consider adverse effects, next-day impairment, and dependence risk.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It is not a substitute for the official patient leaflet, full prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed. Eszopiclone tablets, for oral use, CIV. Official prescribing information and boxed warning. View prescribing information
- Philip I Hair et al. Eszopiclone: a review of its use in the treatment of insomnia. Drugs, 2008. View scientific article
- Jiefang Road 238 et al. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Sleep, 2019. View scientific article
